Cargando…

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status

Poly (ADP-ribose) polymerase inhibitors (PARPi) have proven to be beneficial to patients with metastatic breast cancer with BRCA1/2 (BReast CAncer type 1 and type 2 genes) mutations. However, certain PARPi in pre-clinical studies have been shown to inhibit cell growth and promote the death of breast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keung, Man Yee, Wu, Yanyuan, Badar, Francesca, Vadgama, Jaydutt V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231148/ https://www.ncbi.nlm.nih.gov/pubmed/32235451 http://dx.doi.org/10.3390/jcm9040940

Ejemplares similares

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
por: Keung, Man Yee T., et al.
Publicado: (2019)

Transcriptional Regulation of CCL2 by PARP1 Is a Driver for Invasiveness in Breast Cancer
por: Dutta, Pranabananda, et al.
Publicado: (2020)

Genetic variants in African-American and Hispanic patients with breast cancer
por: Dutta, Pranabananda, et al.
Publicado: (2022)

Epithelial-Mesenchymal Transition and Breast Cancer
por: Wu, Yanyuan, et al.
Publicado: (2016)

GROα overexpression drives cell migration and invasion in triple negative breast cancer cells
por: Bhat, Kruttika, et al.
Publicado: (2017)

STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits
por: CHUNG, SEYUNG S., et al.
Publicado: (2013)

MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis
por: Dutta, Pranabananda, et al.
Publicado: (2018)

Triple Negative Breast Tumors in African-American and Hispanic/Latina Women Are High in CD44+, Low in CD24+, and Have Loss of PTEN
por: Wu, Yanyuan, et al.
Publicado: (2013)

Expression of MALAT1 Promotes Trastuzumab Resistance in HER2 Overexpressing Breast Cancers
por: Wu, Yanyuan, et al.
Publicado: (2020)

Association of Vitamin D3 Level with Breast Cancer Risk and Prognosis in African-American and Hispanic Women
por: Wu, Yanyuan, et al.
Publicado: (2017)

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
por: Bizzaro, Francesca, et al.
Publicado: (2021)

Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation
por: Wu, Yanyuan, et al.
Publicado: (2010)

Phytochemicals in Inhibition of Prostate Cancer: Evidence from Molecular Mechanisms Studies
por: Hao, Qiongyu, et al.
Publicado: (2022)

Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women
por: Wu, Yanyuan, et al.
Publicado: (2022)

Estrogen receptor-beta is a potential target for triple negative breast cancer treatment
por: Austin, David, et al.
Publicado: (2018)

IGF-1 Regulates Cyr61 Induced Breast Cancer Cell Proliferation and Invasion
por: Sarkissyan, Suren, et al.
Publicado: (2014)

Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer
por: Wu, Yanyuan, et al.
Publicado: (2008)

Tumor-Derived Exosomes in Tumor-Induced Immune Suppression
por: Hao, Qiongyu, et al.
Publicado: (2022)

The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients
por: Elshimali, Yahya I., et al.
Publicado: (2013)

Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets
por: Nava, Miguel, et al.
Publicado: (2019)

Roles of Protein Disulfide Isomerase in Breast Cancer
por: Yang, Suhui, et al.
Publicado: (2022)

Activation of Akt1 accelerates carcinogen-induced tumorigenesis in mammary gland of virgin and post-lactating transgenic mice
por: Wu, Yanyuan, et al.
Publicado: (2014)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Utilization of NGS technologies to investigate transcriptomic and epigenomic mechanisms in trastuzumab resistance
por: Nava, Miguel, et al.
Publicado: (2019)

PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
por: Frizzell, Kristine M, et al.
Publicado: (2009)

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
por: Menezes, Maria Clara Saad, et al.
Publicado: (2022)

TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status
por: Ben Khaled, Najib, et al.
Publicado: (2022)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer
por: Hamilton, Nalo, et al.
Publicado: (2017)

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
por: Petrelli, Annalisa, et al.
Publicado: (2023)

PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival
por: Shao, Fengping, et al.
Publicado: (2021)

Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches
por: Dilmac, Sayra, et al.
Publicado: (2023)

Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2023)

Optimization Of Cancer Treatment Through Overcoming Drug Resistance
por: Elshimali, Yahya I., et al.
Publicado: (2018)

Vitamin D Receptor Gene Polymorphisms and Prognosis of Breast Cancer among African-American and Hispanic Women
por: Mishra, Dhruva K., et al.
Publicado: (2013)

A83-01 inhibits TGF-β-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells
por: Wu, Yanyuan, et al.
Publicado: (2017)

Celecoxib in breast cancer prevention and therapy
por: Li, Jieqing, et al.
Publicado: (2018)

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells
por: Arun, Banu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_skeou40ecflafa63oergvuci8v